This trial will study if people with liver problems can safely take a new medicine, pacritinib, and how the medicine works in these people.
- Liver Disease
1 Primary · 6 Secondary · Reporting Duration: Day 14 ARAUC0-12
Awards & Highlights
3 Treatment Groups
Moderate Hepatic Impairment
1 of 3
Severe Hepatic Impairment
1 of 3
Normal Hepatic Function
1 of 3
32 Total Participants · 3 Treatment Groups
Primary Treatment: Moderate Hepatic Impairment · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18 - 85 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any unfilled slots available in this clinical trial?
"Clinicaltrials.gov confirms that this medical trial is still recruiting, having been posted on December 12th 2022 and refreshed lastly on May 8th 2023." - Anonymous Online Contributor
How many participants are currently participating in the research?
"Affirmative. According to clinicaltrials.gov, the information pertaining to this trial was first posted on December 12th 2022 and recently updated on May 8th 2023. The study is searching for 32 individuals who will be based out of a single site." - Anonymous Online Contributor
Does the trial have any age restrictions for participants?
"This medical trial is open to patients aged 18-85. There are 24 studies available for minors and 240 experiments that cater to seniors over 65 years old." - Anonymous Online Contributor
Who is eligible to enroll in this medical study?
"This clinical trial is currently recruiting 32 participants with liver disease, aged between 18 and 85. Eligibility requirements for enrolment include the ability to give written informed consent; having a BMI of 18-42 kg/m2; being surgically sterile, postmenopausal or willing to use an acceptable form of birth control (for female subjects); refraining from sperm donation (for male subjects); having chronic hepatic impairment as assessed by Child-Pugh classification score 7-15 points; being judged in good general health based on medical history, laboratory assessments and physical examination findings; and finally - normal hepatic function." - Anonymous Online Contributor
To what degree are individuals affected by Moderate Hepatic Impairment?
"Our internal assessment provided Moderate Hepatic Impairment with a score of 1 due to the lack of safety and efficacy data available in its Phase 1 clinical trial." - Anonymous Online Contributor